Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
NCT00048737Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2002
- Primary completion
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2002; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00048737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048737.